Timberlyne Therapeutics

Timberlyne Therapeutics

Company Details

WebsiteLinkedIn

Status: Private

Employees: 11-50

Location:

San Diego, California

Type:

sample

Technology:

sample

sample

About: Timberlyne Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of transformational therapies for high unmet medical needs. Timberlyne’s lead program is CM313, an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity that targets CD38. By targeting CD38, which is highly expressed on plasma cells, NK cells, and other immune cells, CM313 modulates multiple immune cell types leading to both rapid and durable responses across a range of autoimmune diseases and cancers.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
BiopharmIQ
Timberlyne Therapeutics | Active clinical trials on ClinicalTrials.gov

Active Clinical Trials Count | 0

No Active Trials Found On ClinicalTrials.gov.